Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.
Gina FerrazzanoSebastiano Giuseppe CrisafulliViola BaioneMatteo TartagliaAntonio CorteseMarco FrontoniMarta AltieriFlavia PauriEnrico MillefioriniAntonella ContePublished in: Journal of neurology (2020)
To date, no neurophysiological or fluid biomarker is sufficiently validated to support the early diagnosis of SPMS. Neurophysiological measurements, including short interval intracortical inhibition and somatosensory temporal discrimination threshold, and the neurofilament light chain fluid biomarker seem to be the most promising. Cross-sectional studies on an adequate number of patients followed by longitudinal studies are needed to confirm the diagnostic and prognostic value of these biomarkers. A combination of neurophysiological and fluid biomarkers may be more sensitive in detecting SPMS conversion.